Advertisement
News

MAVERICK study indicates possible improved cognitive outcomes for patients with SCLC

Make CHEST Physician® a trusted source
Chad G. Rusthoven, MD
Chad G. Rusthoven, MD

Preliminary results of a trial support the idea that regular MRI surveillance alone may allow earlier detection of brain metastases and more effective salvage treatment, which could mean that the survival benefit previously observed with prophylactic cranial irradiation (PCI) for patients with small-cell lung cancer (SCLC) may no longer exist when compared with MRI.

Chad G. Rusthoven, MD, principal investigator of the international phase III SWOG S1827/MAVERICK trial of brain MRI surveillance with or without PCI for SCLC, said the trial showed that patients assigned to MRI surveillance alone had better cognitive failure-free survival and fewer treatment-related adverse events, without a significant difference in progression-free survival or in the preliminary analysis of overall survival, compared with patients assigned to MRI plus PCI.

“Regular MRI surveillance allows us to monitor patients closely and to treat brain metastases when they occur, while avoiding the potential side effects of routine radiation to the entire brain,” Dr. Rusthoven said. “In my view, these results support MRI surveillance alone as the preferred approach for patients with SCLC who have no brain metastases on MRI after initial therapy.”

Dr. Rusthoven, Adjoint Associate Professor of Radiation Oncology at the University of Colorado Anschutz School of Medicine, Aurora, presented yet-to-be-published results from the study in September at the 2026 World Conference on Lung Cancer in Seoul, Republic of Korea, and at the 2026 American Society for Radiation Oncology conference in Boston.

Dr. Rusthoven noted that the role of PCI has evolved as MRI use for staging and surveillance becomes more widespread. Studies before MRI became routine showed that PCI provided an overall survival benefit.1,2 However, that benefit has been balanced by concerns that PCI, which is applied to the entire brain, causes impairment of cognitive function. Despite these concerns, PCI has remained a standard option for patients with both limited-stage and extensive-stage disease because existing studies have yielded conflicting results.

A phase 3 trial in Japan randomized patients with extensive-stage SCLC to MRI surveillance with or without PCI and reported no significant difference in overall survival.3 However, randomized data had been lacking for patients with limited-stage SCLC.

MAVERICK is the first randomized phase 3 trial evaluating MRI surveillance with or without PCI in patients with either limited-stage or extensive-stage SCLC. In MAVERICK, 68% of patients had limited-stage disease.

Dr. Rusthoven said that patients managed with MRI surveillance alone had significantly better cognitive failure-free survival (CFFS) at a follow-up of 22 months (HR, 0.60; 90% CI, 0.46-0.78; P = .0005). Investigators used standardized tests to assess cognitive outcomes.

Of those receiving PCI, 77% received hippocampal-avoidance (HA)-PCI. Subgroup analyses of patients receiving HA-PCI vs MRI surveillance alone demonstrated nearly identical CFFS benefits with MRI surveillance alone compared with the overall cohort.

“The CFFS benefit of MRI surveillance alone appeared consistent in both limited-stage and extensive-stage SCLC and did not differ significantly according to receipt of immunotherapy,” Dr. Rusthoven said. “These findings suggest broad applicability of the observed benefits of MRI surveillance alone.”

The key secondary end point was overall survival. Preliminary analysis after 128 deaths suggests no significant difference in overall survival between treatment groups, with the final overall survival to be done after 190 deaths. The hazard ratio for MRI surveillance alone compared with MRI surveillance plus PCI was 0.90 (90% CI, 0.67-1.20). There was no significant difference observed between the two strategies regarding progression-free survival. The MRI-alone arm resulted in fewer treatment-related toxicities and avoided the side effects associated with exposing the entire brain to radiation.

At the World Conference on Lung Cancer, study discussant Hideyuki Harada, MD, PhD, Chief of the Division of Radiation Therapy at Shizuoka Cancer Center, noted that in the MRI-alone arm of MAVERICK, the brain was the site of first progression in 18% of patients. Regardless of whether it is prophylactic or therapeutic, he said, these patients would benefit from cranial irradiation.

“If an MRI surveillance strategy cannot be adopted, no PCI and no MRI surveillance would be harmful in these patients. If MRI surveillance could not be adopted, PCI should be considered for the patient,” Dr. Harada said during the presentation. “When MRI surveillance becomes the [standard of care], the accessibility [of MRI] becomes an important issue.”

The key takeaways include:

  • No overall survival difference: Preliminary data show no significant difference in overall survival between patients who receive regular MRI surveillance alone vs those who receive MRI plus PCI.
  • Better cognitive outcomes: Patients assigned to MRI surveillance alone experienced significantly better CFFS and fewer treatment-related adverse events.
  • Hippocampal avoidance limitations: The cognitive benefits of MRI surveillance alone remained consistent even when compared against HA-PCI.
  • Broad applicability: These benefits were consistent across both limited-stage and extensive-stage SCLC, regardless of whether patients received immunotherapy.

References

1. Aupérin A, Arriagada R, Pignone JP, et al; Prophylactic Cranial Irradiation Overview Collaborative Group. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. N Engl J Med. 1999;341(7):476-484. doi:10.1056/NEJM199908123410703

2. Slotman B, Faivre-Finn C, Kramer G, et al. Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med. 2007;357(7):664-672. doi:10.1056/NEJMoa071780

3. Takahashi T, Yamanaka T, Seto T, et al. Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2017;18(5):663-671. doi:10.1016/S1470-2045(17)30230-9